DMV International is part of Campina, an international dairy co-operative focusing on the development, production, sales and distribution of dairy products. Selling products in over 100 countries, Campina is one of the most important partners of the largest European supermarket chains and the global food and pharmaceutical industry.
Steve Braun, director of Food Systems & Nutrition, went into further detail about the company’s core competency. “Our nutritionals group’s focus has always revolved around the separation and fractionation of proteins from various streams for use in infant formula, microbiological media, sports nutrition products and supplements,” he said. “These proteins and peptides are geared toward our two research platforms, immunity and heart health.”
In the heart health arena, DMV offers products such as its C12 Peption, which can be used in blood pressuring lowering formulations. In March, the company received the “2005 NutrAward-2004 Ingredient of the Year” for its C12 Peption. “Winning the NutrAward is a great recognition for the innovative character of this product. The fact that both a scientific committee and the visitors selected C12 Peption as the winner proves its sound scientific basis and market potential,” said Mr. Braun. The recipient of the NutrAward is chosen every year by the attendees of Nutracon/Supply Expo and its scientific committee.
For immune health applications, the company recently launched Cysteine Peption. Mr. Braun also said the company continues to market its intact protein lactoferrin. Most recently, however, he said another use for lactoferrin has been discovered. “Researchers at DMV believe that the immunity/anti-inflammatory effects of lactoferrin can also be beneficial to those who have acne if taken orally,” Mr. Braun explained.
While lactoferrin is used in some topical treatments for acne, an oral application has never been investigated. So DMV conducted a clinical study with 40 high school students, who ingested a lactoferrin-based product for a period of 12 weeks. Comparative pictures were taken throughout the study and evaluated by dermatologists. The dermatologists looked at the relative numbers of pimples, blackheads and other blemishes. “The pictures turned out to be quite dramatic,” Mr. Braun said. “Now that the scientists have had a chance to take a look at this product, they have a pretty good idea what the mechanism of action might be.” DMV has filed a patent for this application and calls the new product Praventin. Mr. Braun believes this will be an interesting area for the company going forward.
For the future, Mr. Braun says research will remain a cornerstone for DMV. As for the overall supplement industry, he said the scientific evidence will only continue to grow. “Five years ago supplements were booming and then the market contracted substantially. Now the industry is growing at a reasonable rate and I think it is much healthier than it has ever been,” he explained. “What you see now is many more companies demanding ‘proven’ products, real science. The industry will continue to build on that. Research seems to be the price of entry now, which is good for the overall integrity and future growth of the market.”
From a functional foods perspective, Mr. Braun added, “Growth in the functional foods category is slowly coming. What the market has witnessed so far are a lot of missteps, but the market continues to learn from those mistakes. The next generation of functional foods will be much different from the first. And there will definitely be a lot more science and thought put into how functional food products are positioned.”—R.W.
40196 State Highway 10
Delhi, NY 13753